The Bacterial Second Messenger Cyclic Di-GMP Regulates Brucella Pathogenesis and Leads to Altered Host Immune Response
Overview
Authors
Affiliations
Brucella species are facultative intracellular bacteria that cause brucellosis, a chronic debilitating disease significantly impacting global health and prosperity. Much remains to be learned about how Brucella spp. succeed in sabotaging immune host cells and how Brucella spp. respond to environmental challenges. Multiple types of bacteria employ the prokaryotic second messenger cyclic di-GMP (c-di-GMP) to coordinate responses to shifting environments. To determine the role of c-di-GMP in Brucella physiology and in shaping host-Brucella interactions, we utilized c-di-GMP regulatory enzyme deletion mutants. Our results show that a ΔbpdA phosphodiesterase mutant producing excess c-di-GMP displays marked attenuation in vitro and in vivo during later infections. Although c-di-GMP is known to stimulate the innate sensor STING, surprisingly, the ΔbpdA mutant induced a weaker host immune response than did wild-type Brucella or the low-c-di-GMP guanylate cyclase ΔcgsB mutant. Proteomics analysis revealed that c-di-GMP regulates several processes critical for virulence, including cell wall and biofilm formation, nutrient acquisition, and the type IV secretion system. Finally, ΔbpdA mutants exhibited altered morphology and were hypersensitive to nutrient-limiting conditions. In summary, our results indicate a vital role for c-di-GMP in allowing Brucella to successfully navigate stressful and shifting environments to establish intracellular infection.
STING-Pathway Inhibiting Nanoparticles (SPINs) as a Platform for Treatment of Inflammatory Diseases.
Pastora L, Namburu N, Arora K, Christov P, Wilson J ACS Appl Bio Mater. 2024; 7(8):4867-4878.
PMID: 38563162 PMC: 11337154. DOI: 10.1021/acsabm.3c01305.
and biofilm dispersal from microplastics influenced by simulated human environment.
Leighton R, Xiong L, Anderson G, Astarita G, Cai G, Norman R Front Microbiol. 2023; 14:1236471.
PMID: 37854331 PMC: 10579612. DOI: 10.3389/fmicb.2023.1236471.
Alakavuklar M, Fiebig A, Crosson S Annu Rev Microbiol. 2023; 77:233-253.
PMID: 37104660 PMC: 10787603. DOI: 10.1146/annurev-micro-032521-013159.
Activation of mucosal immunity as a novel therapeutic strategy for combating brucellosis.
Pascual D, Goodwin Z, Bhagyaraj E, Hoffman C, Yang X Front Microbiol. 2023; 13:1018165.
PMID: 36620020 PMC: 9814167. DOI: 10.3389/fmicb.2022.1018165.
Zhang Z, Zhou H, Ouyang X, Dong Y, Sarapultsev A, Luo S Signal Transduct Target Ther. 2022; 7(1):394.
PMID: 36550103 PMC: 9780328. DOI: 10.1038/s41392-022-01252-z.